# Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

> **NCT02068586** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 210 (estimated)

## Conditions studied

- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Ciliary Body and Choroid Melanoma, Small Size
- Iris Melanoma
- Stage I Intraocular Melanoma
- Stage IIA Intraocular Melanoma
- Stage IIB Intraocular Melanoma
- Stage IIIA Intraocular Melanoma
- Stage IIIB Intraocular Melanoma
- Stage IIIC Intraocular Melanoma
- Stage I Uveal Melanoma AJCC V7
- Stage II Uveal Melanoma AJCC V7
- Stage III Uveal Melanoma AJCC V7

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Valproic Acid
- **DRUG:** Sunitinib Malate
- **DRUG:** Sunitinib Malate + Valproic Acid

## Key facts

- **NCT ID:** NCT02068586
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-11-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02068586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02068586, "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02068586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*